GGrantIndex
← Leaderboards

Jeffrey A Sosman

University Of Illinois At Chicago

Google Scholar ↗PubMed ↗ORCID ↗
$7,988,701
Attributed
$8,968,085
Total exposure
15
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $882.3K · FY2005–25
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,168,086 · 13
FDA$799,999 · 2

By mechanism

R01$3,376,771 · 4
P30$2,114,940 · 1
K24$1,538,406 · 1
N01$1,220,533 · 1
U10$477,478 · 1
M01$239,957 · 7

Top collaborators

Others in their field

Top investigators on “Clinical Trials”

Research focus

Clinical TrialsInstitutionGrantResearch PersonnelToxic EffectResponseFundingBaseResourcesCancer TherapyPre-ClinicalTumorMelanomaPathway InteractionsMolecularSourceAwardImatinibHuman SubjectMalignant NeoplasmsTrainingNeoplasm /Cancer ImmunologyNeoplasm /Cancer ImmunotherapyClinical Research

Grant awards (34)

Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity$663,989
R01 · FY2025 · CA
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity$630,790
R01 · FY2024 · CA
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity$663,989
R01 · FY2023 · CA
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma$400,000
R01 · FY2013 · FD · contact PI
Clinical Investigation in Tumor Immunotherapy$173,520
K24 · FY2012 · CA · contact PI
Clinical Investigation in Tumor Immunotherapy$173,520
K24 · FY2011 · CA · contact PI
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma$399,999
R01 · FY2010 · FD · contact PI
Clinical Investigation in Tumor Immunotherapy$173,520
K24 · FY2010 · CA · contact PI
Clinical Investigation in Tumor Immunotherapy$173,520
K24 · FY2009 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$710,642
P30 · FY2008 · CA · contact PI
Clinical Investigation in Tumor Immunotherapy$170,584
K24 · FY2008 · CA · contact PI
PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB$668
M01 · FY2008 · RR · contact PI
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C$375
M01 · FY2008 · RR · contact PI
CLINICAL TRIALS SHARED RESOURCE$686,777
P30 · FY2007 · CA · contact PI
PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB$14,172
M01 · FY2007 · RR · contact PI
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C$7,957
M01 · FY2007 · RR · contact PI
CLINICAL TRIALS SHARED RESOURCE$246,277
P30 · FY2006 · CA · contact PI
Clinical Investigation in Tumor Immunotherapy$135,488
K24 · FY2006 · CA · contact PI
PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB$56,210
M01 · FY2006 · RR · contact PI
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C$33,138
M01 · FY2006 · RR · contact PI
Overcoming DC defects in cancer patients by VEGF trap$296,477
R01 · FY2005 · CA
CLINICAL TRIALS SHARED RESOURCE$239,104
P30 · FY2005 · CA
Clinical Investigation in Tumor Immunotherapy$135,107
K24 · FY2005 · CA
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C$77,370
M01 · FY2005 · RR
Overcoming DC defects in cancer patients by VEGF trap$68,025
R01 · FY2005 · CA
Inhibition of nf-kb signaling in melanoma therapy$0
R01 · FY2005 · FD
Overcoming DC defects in cancer patients by VEGF trap$253,502
R01 · FY2004 · CA
CLINICAL TRIALS SHARED RESOURCE$232,140
P30 · FY2004 · CA
Clinical Investigation in Tumor Immunotherapy$134,738
K24 · FY2004 · CA
PHI-0241- A phase I/II clinical trial of PS-341, a proteasome Inhibitor, in c...$50,067
M01 · FY2004 · RR
Clinical Investigation in Tumor Immunotherapy$134,379
K24 · FY2003 · CA
Clinical Investigation in Tumor Immunotherapy$134,030
K24 · FY2002 · CA
PHASE I SINGLE &MULTIPLE DOSE SAFETY &PHARMACOKINETICS$1,220,533
N01 · FY2000 · CN
MINORITY BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM$477,478
U10 · FY2000 · CA